{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:35:05Z","timestamp":1787841305769,"version":"build-2784847793"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective\/Background:<\/jats:title>\n                    <jats:p>Chimeric antigen receptor (CAR) T-cell is an effective therapy in relapsed\/refractory large B-cell lymphomas that, due to its unique toxicities, often requires escalation of care to the intensive care unit (ICU) setting. C-reactive protein (CRP) and ferritin are serum inflammatory markers associated with onset and persistence of CAR T-cell-related toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      We retrospectively analyzed 34 patients treated with axicabtagene ciloleucel (axi- cel) who were divided into two groups: patients requiring admission to the ICU during initial hospitalization (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 13, 38%) and those who did not (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 21, 62%). Primary objective was to examine possible relationships between serum ferritin and\/or CRP levels with the need for, and length of, ICU stay between these groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      All 13 patients admitted to the ICU developed cytokine release syndrome (CRS) and 11 of them also developed neurotoxicity (NT). Of the 21 patients in the non-ICU group, 18 developed CRS and 5 patients developed NT. Grade of CRS and NT were higher in ICU versus non-ICU patients (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .03 and .001, respectively). There was no correlation between CRP levels at time of ICU admission and length of ICU stay (correlation of 0.41,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .17). Yet, there was an association between serum ferritin levels and length of ICU stay (\n                      <jats:italic toggle=\"yes\">R<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 0.73) which did not reach statistical significance (correlation of 0.21,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .49).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Notwithstanding the limitations of the small sample size, our study suggests that an elevated ferritin level at the time of escalation of medical care may be possibly indicative of anticipated prolonged ICU hospitalization in patients treated with axi-cel. A large multicenter study is certainly needed to confirm this observation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2020.09.004","type":"journal-article","created":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T21:30:43Z","timestamp":1602538243000},"page":"141-146","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel \u2606"],"prefix":"10.4103","volume":"14","author":[{"given":"Megan","family":"Melody","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaid Abdel","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hollie","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula Lengerke","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Gannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han W.","family":"Tun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Foran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Januario E.","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramod","family":"Guru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-9-20241211","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"R3-9-20241211","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"R4-9-20241211","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1097\/HS9.0000000000000191","article-title":"In the eye of the storm: immune-mediated toxicities associated with CAR-T cell therapy","volume":"3","author":"Garcia","year":"2019","journal-title":"Hemasphere"},{"key":"R5-9-20241211","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R6-9-20241211","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy \u2013 assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R7-9-20241211","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/bloodadvances.2019000952","article-title":"Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management","volume":"4","author":"Pennisi","year":"2020","journal-title":"Blood Adv"},{"key":"R8-9-20241211","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/CNQ.0000000000000302","article-title":"CAR T-cell-associated neurotoxicity: current management and emerging treatment strategies","volume":"43","author":"Rivera","year":"2020","journal-title":"Crit Care Nurs Q"},{"key":"R10-9-20241211","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/10428194.2018.1482540","article-title":"Prognostic value of pre-therapy C-reactive protein level in diffuse large B-cell lymphoma: a meta-analysis","volume":"60","author":"Qin","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"R11-9-20241211","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12885-017-3931-z","article-title":"An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era","volume":"18","author":"Sun","year":"2018","journal-title":"BMC Cancer"},{"key":"R12-9-20241211","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/bjc.2014.277","article-title":"C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients","volume":"111","author":"Troppan","year":"2014","journal-title":"Br J Cancer"},{"key":"R13-9-20241211","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.cca.2016.05.033","article-title":"Pretreatment C-reactive protein was an independent prognostic factor for patients with diffuse large B-cell lymphoma treated with RCHOP","volume":"459","author":"Wang","year":"2016","journal-title":"Clin Chim Acta"},{"key":"R14-9-20241211","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13613-016-0105-0","article-title":"Elevated C-reactive protein levels at ICU discharge as a predictor of ICU outcome: a retrospective cohort study","volume":"6","author":"Gulcher","year":"2016","journal-title":"Ann Intensive Care"},{"key":"R15-9-20241211","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.jcrc.2011.10.013","article-title":"Failure to reduce C-reactive protein levels more than 25% in the last 24 hours before intensive care unit discharge predicts higher in-hospital mortality: a cohort study","volume":"27","author":"Ranzani","year":"2012","journal-title":"J Crit Care"},{"key":"R16-9-20241211","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"R17-9-20241211","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/pbc.21423","article-title":"Highly elevated ferritin levels and the diagnosis of hemophagocytic lympho-histiocytosis","volume":"50","author":"Allen","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"R18-9-20241211","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev-pathol-020117-043625","article-title":"Hemophagocytic lymphohistiocytosis","volume":"13","author":"Al-Samkari","year":"2018","journal-title":"Annu Rev Pathol"},{"key":"R19-9-20241211","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1039\/C3MT00347G","article-title":"Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells","volume":"6","author":"Kell","year":"2014","journal-title":"Metallomics"},{"key":"R20-9-20241211","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"R21-9-20241211","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/PPO.0000000000000377","article-title":"Management of T-cell engaging immunotherapy complications","volume":"25","author":"Varadarajan","year":"2019","journal-title":"Cancer J"},{"key":"R22-9-20241211","first-page":"245","article-title":"The significance of ferritin in cancer: anti-oxidation, inflammation and tumorigenesis","volume":"1836","author":"Alkhateeb","year":"2013","journal-title":"Biochim Biophys Acta"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387620301515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387620301515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2020.09.004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:49:04Z","timestamp":1787838544000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2020.09.004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2020.09.004","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]}}}